Unlikely allies MSD, Cipla link to co-market Isentress in India
This article was originally published in Scrip
MSD (as Merck & Co is known outside the US and Canada) and Cipla, never really considered natural allies, have now formed an India-specific partnership, under which Cipla will co-market the US firm's HIV drug Isentress (raltegravir).
You may also be interested in...
Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.